Catalyst Biosciences (CBIO +20%) spikes higher following a positive update
on its Phase 2 study of dalcinonacog alfa ((DalcA)), a next-generation
subcutaneously administered Factor IX therapy being developed for the
treatment of hemophilia B.
CBIO says two subjects have completed dosing and
washout, and Factor IX levels in the subjects exceeded the trial
efficacy endpoint of greater than 12% activity and no anti-drug
antibodies were detected.
The trial is expected to enroll up to six
completing subjects who will receive a single intravenous dose, followed
by daily subcutaneous doses of DalcA for 28 days; CBIO expects to
report final data in H1 2020.
https://seekingalpha.com/news/3503837-catalyst-bio-reports-positive-trial-update-blood-disorder-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.